A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy

S Pignata; F Amant; Giovanni Scambia; R Sorio; E Breda; W Rasch; K Hernes; C Pisano; K Leunen; Domenica Lorusso; L Cannella; I. Vergote

doi:10.1007/s00280-011-1735-4

A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy

S Pignata, F Amant, Giovanni Scambia, R Sorio, E Breda, W Rasch, K Hernes, C Pisano, K Leunen, Domenica Lorusso, L Cannella, I. Vergote

Research output: Contribution to journal › Article

10 Citations (Scopus)

Abstract

Treatment of patients with recurrent ovarian cancer remains a challenge, and there is a need for new and more effective agents. A phase I-II study was designed to determine the recommended dose (RD) and the anti-tumour effect of a prolonged administration of elacytarabine, the elaidic ester of cytarabine, in patients with refractory/resistant recurrent ovarian cancer.

Original language	English
Pages (from-to)	1347-1353
Number of pages	7
Journal	Cancer Chemotherapy and Pharmacology
Volume	68
DOIs	https://doi.org/10.1007/s00280-011-1735-4
Publication status	Published - 2011

Keywords

Antimetabolites, Antineoplastic
Cytarabine
Female
Humans
Middle Aged
Ovarian Neoplasms

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00280-011-1735-4

Cite this

Pignata, S., Amant, F., Scambia, G., Sorio, R., Breda, E., Rasch, W., Hernes, K., Pisano, C., Leunen, K., Lorusso, D., Cannella, L., & Vergote, I. (2011). A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy. Cancer Chemotherapy and Pharmacology, 68, 1347-1353. https://doi.org/10.1007/s00280-011-1735-4

@article{b5656bf03f70421fb034d5c5f4a18775,

title = "A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy",

abstract = "Treatment of patients with recurrent ovarian cancer remains a challenge, and there is a need for new and more effective agents. A phase I-II study was designed to determine the recommended dose (RD) and the anti-tumour effect of a prolonged administration of elacytarabine, the elaidic ester of cytarabine, in patients with refractory/resistant recurrent ovarian cancer.",

keywords = "Antimetabolites, Antineoplastic, Cytarabine, Female, Humans, Middle Aged, Ovarian Neoplasms, Antimetabolites, Antineoplastic, Cytarabine, Female, Humans, Middle Aged, Ovarian Neoplasms",

author = "S Pignata and F Amant and Giovanni Scambia and R Sorio and E Breda and W Rasch and K Hernes and C Pisano and K Leunen and Domenica Lorusso and L Cannella and I. Vergote",

year = "2011",

doi = "10.1007/s00280-011-1735-4",

language = "English",

volume = "68",

pages = "1347--1353",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "0344-5704",

publisher = "Springer Science and Business Media Deutschland GmbH",

}

Pignata, S, Amant, F, Scambia, G, Sorio, R, Breda, E, Rasch, W, Hernes, K, Pisano, C, Leunen, K, Lorusso, D, Cannella, L & Vergote, I 2011, 'A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy', Cancer Chemotherapy and Pharmacology, vol. 68, pp. 1347-1353. https://doi.org/10.1007/s00280-011-1735-4

TY - JOUR

T1 - A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy

AU - Pignata, S

AU - Amant, F

AU - Scambia, Giovanni

AU - Sorio, R

AU - Breda, E

AU - Rasch, W

AU - Hernes, K

AU - Pisano, C

AU - Leunen, K

AU - Lorusso, Domenica

AU - Cannella, L

AU - Vergote, I.

PY - 2011

Y1 - 2011

N2 - Treatment of patients with recurrent ovarian cancer remains a challenge, and there is a need for new and more effective agents. A phase I-II study was designed to determine the recommended dose (RD) and the anti-tumour effect of a prolonged administration of elacytarabine, the elaidic ester of cytarabine, in patients with refractory/resistant recurrent ovarian cancer.

AB - Treatment of patients with recurrent ovarian cancer remains a challenge, and there is a need for new and more effective agents. A phase I-II study was designed to determine the recommended dose (RD) and the anti-tumour effect of a prolonged administration of elacytarabine, the elaidic ester of cytarabine, in patients with refractory/resistant recurrent ovarian cancer.

KW - Antimetabolites, Antineoplastic

KW - Cytarabine

KW - Female

KW - Humans

KW - Middle Aged

KW - Ovarian Neoplasms

KW - Antimetabolites, Antineoplastic

KW - Cytarabine

KW - Female

KW - Humans

KW - Middle Aged

KW - Ovarian Neoplasms

UR - http://hdl.handle.net/10807/3738

U2 - 10.1007/s00280-011-1735-4

DO - 10.1007/s00280-011-1735-4

M3 - Article

SN - 0344-5704

VL - 68

SP - 1347

EP - 1353

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

ER -

A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this